In this issue of Blood, Shah et al describe the onset of severe acute graft-versus-host disease (GVHD) in 5 of 9 patients who received infusions of ex vivo expanded donor natural killer (NK) cells after HLA-matched hematopoietic stem cell transplantation (HSCT).